目的:探讨尤瑞克林治疗急性进展性脑梗死的近期疗效.方法:将97例急性进展性脑梗死患者随机分为尤瑞克林治疗组(49例)和对照组(48例).两组均给予抗血小板药、脑保护、调整血压、康复等治疗,治疗组同时给予尤瑞克林0.15 PNAU加入0.9%氯化钠注射液100 ml中静脉滴注,每日 1次,连用10～14 d,于治疗前后评定神经功能缺损程度(Chinese Stroke Scale,CSS)、日常生活能力评价(activities of daily living,ADL)和临床疗效.结果:治疗组患者的CSS、ADL评分均显著高于对照组(P＜0.01),临床有效率为86.2%,近期治愈率为50.8%,显著高于对照组(P＜0.05).且无明显不良反应.结论:尤瑞克林治疗急性进展性脑梗死有一定效果.%Objective: To investigate the effect of Urinary Kallidinogenase on acute progressive cerebral infarction. Methods: 137 patients with acute progressive cerebral infarction were randomly divided into two groups treatment group with Urinary Kallidinogenase (n=78) and control group (n=79). Two groups were treated with basic therapy, such as antiplatelet,neurologic protection, blood pressure control, nerve recovery and so on. On basis of control group, treatment group was administrated intravenous injection of Urinary Kallidinogenase 0.15 PNAU per day for 10-14 days. The primary efficacy was evaluated by CSS (Chinese Stroke Scale, CSS), ADJ. (Activities of daily living, ADL) and clinical effective. Results: Our study showed that the scores in CSS and ADL in the treatment group was higher than those of control group, Urinary Kallidinogenase could significantly reduce neurological deficits and the effective rate was 86.2％, curative rate of recent period was 50.8％ compared with control group. Conclusion: Unnary Kallidinogenase is maybe effective and safe in the treatment of acute progressive cerebral infarction.
展开▼
